Metabolomics and Clinical Data for Sintilimab-Induced Rash in Lung Cancer Patients

55 lung cancer patients receiving sintilimab immunotherapy, including 32 who developed rash and 23 matched controls. Plasma metabolomic profiles and clinical parameters were analyzed using UHPLC–MS/MS and machine learning techniques. The dataset was published by Wenxiu Tian on figshare in June 2026.

Use Cases

• Identifying predictive biomarkers for drug-induced rash based on differential metabolite analysis
• Investigating metabolic pathway alterations associated with immunotherapy side effects
• Training machine learning models for adverse event prediction using SHAP analysis results
• Correlating clinical parameters like bile acids and basophil percentage with rash incidence

Strengths

• Includes 55 patient records with matched controls for a specific adverse event
• Analyzes 92 differentially expressed metabolites identified via untargeted metabolomics
• Identifies 25 metabolites with high predictive value (AUC ≥0.800) and 5 overlapping key metabolites via SHAP analysis

Limitations

• Dataset size is very small (17.4 KB), indicating limited scope and likely summary data rather than raw observations
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment for large-scale modeling

Provenance

Source

figshare

Collection Method

Blood samples collected before sintilimab infusion and at rash onset, analyzed with UHPLC–MS/MS.

Freshness

Last updated 2026-06-03 05:48:25